IBRANCE 75 mg hard capsules, EXEMESTANE, IBRANCE 125 mg hard capsules, IBRANCE 100 mg hard capsules, IBRANCE 75 mg film-coated tablets, IBRANCE 125 mg hard capsules, IBRANCE 75 mg film-coated tablets, TAMOXIFEN, IBRANCE 75 mg film-coated tablets, IBRANCE 100 mg film-coated tablets, IBRANCE 125 mg film-coated tablets, IBRANCE 125 mg hard capsules, ANASTROZOLE, IBRANCE 75 mg hard capsules, CYCLOPHOSPHAMIDE, DOCETAXEL, IBRANCE 100 mg hard capsules, IBRANCE 100 mg film-coated tablets, IBRANCE 100 mg hard capsul
EORTC-1745-ETF-BCG
Phase 2 small_molecule active
Quick answer
IBRANCE 75 mg hard capsules, EXEMESTANE, IBRANCE 125 mg hard capsules, IBRANCE 100 mg hard capsules, IBRANCE 75 mg film-coated tablets, IBRANCE 125 mg hard capsules, IBRANCE 75 mg film-coated tablets, TAMOXIFEN, IBRANCE 75 mg film-coated tablets, IBRANCE 100 mg film-coated tablets, IBRANCE 125 mg film-coated tablets, IBRANCE 125 mg hard capsules, ANASTROZOLE, IBRANCE 75 mg hard capsules, CYCLOPHOSPHAMIDE, DOCETAXEL, IBRANCE 100 mg hard capsules, IBRANCE 100 mg film-coated tablets, IBRANCE 100 mg hard capsul for Localized ER+ breast cancer is a Phase 2 program (small_molecule) at Cancer Prevention Pharma (Ireland) Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Cancer Prevention Pharma (Ireland) Limited
- Indication
- Localized ER+ breast cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active